Lyell Immunopharma Announces Participation in March Investor Conferences
Rhea-AI Summary
Lyell Immunopharma (Nasdaq: LYEL) said senior management will present at three investor conferences in early March 2026: TD Cowen (Mar 2, Boston), Leerink Annual Global Healthcare (Mar 9, Miami) and Citizens Life Science (Mar 10, Miami).
Live webcasts and on-demand replays will be available on the company website at www.lyell.com following each presentation.
Positive
- None.
Negative
- None.
News Market Reaction – LYEL
On the day this news was published, LYEL gained 6.12%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.9% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $29M to the company's valuation, bringing the market cap to $497M at that time. Trading volume was elevated at 2.2x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows 2 peers (e.g., CADL, ALLO) moving up, but the target’s intraday direction is unspecified, and sector-level momentum is flagged as false, pointing to a company-specific setup around this conference news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Phase 3 trial start | Positive | +4.3% | Initiation of PiNACLE–H2H Phase 3 trial in aggressive LBCL with ronde‑cel. |
| Dec 07 | Clinical data update | Positive | +12.3% | New ASH data showing high durable response rates for ronde‑cel in LBCL. |
| Nov 12 | Earnings and updates | Positive | -1.3% | Q3 2025 results plus RMAT designation and cash runway commentary. |
| Nov 10 | Asset acquisition | Positive | +1.0% | Acquisition of global rights to LYL273 with encouraging Phase 1 mCRC data. |
| Nov 03 | Clinical data preview | Positive | -0.7% | Announcement of upcoming ASH oral presentations for ronde‑cel in LBCL. |
Recent news shows strong clinical updates often met with positive moves, but there are instances where favorable clinical headlines saw flat-to-negative reactions.
Over the past few months, Lyell has focused on advancing its CAR T portfolio, highlighted by Phase 3 initiation in aggressive LBCL on Feb 12, 2026 (+4.27%) and strong ronde‑cel data at ASH on Dec 7, 2025 (+12.32%). Earlier in November, Lyell acquired global rights to LYL273 and reported Q3 2025 results, with mixed price reactions (from -1.25% to +0.97%). Today’s investor conference participation fits within an ongoing campaign to showcase these clinical and business developments.
Regulatory & Risk Context
An effective S-3 resale registration filed on Dec 5, 2025 covers up to 1,900,000 Lyell shares held by Innovative Cellular Therapeutics Holdings Limited. These shares were issued as part of a license agreement, and any sales by the holder would not provide proceeds to Lyell. One related 424B5 filing was recorded on Dec 18, 2025.
Market Pulse Summary
The stock moved +6.1% in the session following this news. A strong positive reaction aligns with Lyell’s pattern of constructive responses to clinical and strategic milestones, such as the ASH data move of +12.32%. However, past events also show occasional pullbacks after good news. Investors would need to weigh enthusiasm from increased conference visibility against existing factors like insider tax-related sales and the resale registration for 1,900,000 shares that could influence secondary-market supply.
Key Terms
car t-cell therapies medical
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the following investor conferences:
- TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, in Boston, Massachusetts; presentation at 9:10am Eastern Time
- Leerink Annual Global Healthcare Conference on Monday, March 9, 2026, in Miami, Florida; fireside chat at 10:00am Eastern Time
- Citizens Life Science Conference on Tuesday, March 10, 2026, in Miami, Florida; fireside chat at 11:55am Eastern Time
A live webcast of each presentation can be accessed through the Investors section of the Company's website at www.lyell.com. Following each live presentation, a replay of the webcast will be available on the Company's website following the presentation date.
About Lyell
Lyell is a clinical stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T cells with enhancements needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness, and function in the hostile tumor microenvironment. Lyell’s LyFE Manufacturing Center™ has commercial launch capability and can manufacture more than 1,200 CAR T-cell doses at full capacity. To learn more, please visit www.lyell.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell management’s planned presentation and participation at investor conferences; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; and the sufficiency of the capacity of LyFE to manufacture drug supply through potential commercial launch. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties described under the heading “Risk Factors” in Lyell’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission on November 12, 2025. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.
Contact:
Peter Tran
Senior Director, Finance
ptran@lyell.com
FAQ
When will Lyell (LYEL) present at the TD Cowen Health Care Conference in 2026?
What time is Lyell's (LYEL) presentation at the Leerink Annual Global Healthcare Conference?
How can investors watch Lyell (LYEL) presentations from the March 2026 conferences?
What is the schedule for Lyell's (LYEL) presentations at the Miami conferences in March 2026?
Will Lyell (LYEL) offer replays of its March 2026 investor presentations?
Which Lyell (LYEL) executives will appear at the March 2026 investor conferences?
